Farnesyl Diphosphate Synthase Gene Associated with Loss of Bone Mass Density and Alendronate Treatment Failure in Patients with Primary Osteoporosis
Open Access
- 22 May 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 5623
Abstract
Aminobisphosphonates (NBPs) are the first-choice medication for osteoporosis (OP); NBP treatment aims at increasing bone mineral density (BMD) by inhibiting the activity of farnesyl diphosphate synthase (FDPS) enzyme in osteoclasts. Despite its efficacy, inadequate response to the drug and side effects have been reported. The A allele of the rs2297480 (A > C) SNP, found in the regulatory region of the FDPS gene, is associated with reduced gene transcription. This study evaluates the FDPS variant rs2297480 (A > C) association with OP patients’ response to alendronate sodium treatment. A total of 304 OP patients and 112 controls were enrolled; patients treated with alendronate sodium for two years were classified, according to BMD variations at specific regions (lumbar spine (L1-L4), femoral neck (FN) and total hip (TH), as responders (OP-R) (n = 20) and non-responders (OP-NR) (n = 40). We observed an association of CC genotype with treatment failure (p = 0.045), followed by a BMD decrease in the regions L1-L4 (CC = −2.21% ± 2.56; p = 0.026) and TH (CC = −2.06% ± 1.84; p = 0.015) after two years of alendronate sodium treatment. Relative expression of the FDPS gene was also evaluated in OP-R and OP-NR patients. Higher expression of the FDPS gene was also observed in OP-NR group (FC = 1.84 ± 0.77; p = 0.006) when compared to OP-R. In conclusion, the influence observed of FDPS expression and the rs2897480 variant on alendronate treatment highlights the importance of a genetic approach to improve the efficacy of treatment for primary osteoporosis.Keywords
Funding Information
- Conselho Nacional de Pesquisa (CNPQ) (001)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES) (001)
- Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco (FACEPE) (001)
This publication has 33 references indexed in Scilit:
- Hip fracture trends in the United States, 2002 to 2015Osteoporosis International, 2017
- The Pathophysiology and Treatment of OsteoporosisClinical Therapeutics, 2015
- Parathyroid hormone: anabolic and catabolic actions on the skeletonCurrent Opinion in Pharmacology, 2015
- Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosisOsteoporosis International, 2014
- Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatinRheumatology International, 2013
- Treatment failure in osteoporosisOsteoporosis International, 2012
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacyOsteoporosis International, 2008
- Farnesyl diphosphate synthase: A novel genotype association with bone mineral density in elderly womenMaturitas, 2007
- Engineered gene over-expression as a method of drug target identificationBiochemical and Biophysical Research Communications, 2005
- Osteoporosis Prevention, Diagnosis, and TherapyJAMA, 2001